Bai J, Li Y, Cai L. Clinical implications of forkhead box M1, cyclooxygenase-2, and glucose-regulated protein 78 in breast invasive ductal carcinoma. World J Clin Cases 2023; 11(30): 7284-7293 [PMID: 37969442 DOI: 10.12998/wjcc.v11.i30.7284]
Corresponding Author of This Article
Li Cai, MD, Doctor, Department of Pathology, Huai’an Maternal and Child Health Care Center, No. 104 Renmin South Road, Qingjiangpu District, Huai’an 223002, Jiangsu Province, China. aa14756893@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 26, 2023; 11(30): 7284-7293 Published online Oct 26, 2023. doi: 10.12998/wjcc.v11.i30.7284
Clinical implications of forkhead box M1, cyclooxygenase-2, and glucose-regulated protein 78 in breast invasive ductal carcinoma
Jie Bai, Ying Li, Li Cai
Jie Bai, Department of Clinical Laboratory, Joint Logistics Support Unit 940 Hospital, Lanzhou 730030, Gansu Province, China
Ying Li, Department of Breast Surgery, The Fourth Hospital of Shijiazhuang, Shijiazhuang 050032, Hebei Province, China
Li Cai, Department of Pathology, Huai’an Maternal and Child Health Care Center, Huai’an 223002, Jiangsu Province, China
Author contributions: Bai J and Cai L designed the research study, analyzed the data, and wrote the manuscript; Bai J, Cai L, and Li Y performed the research, and contributed new reagents and analytic tools; all authors have read and approved the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Joint Logistics Support Unit 940 Hospital.
Informed consent statement: All study participants provided written informed consent.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li Cai, MD, Doctor, Department of Pathology, Huai’an Maternal and Child Health Care Center, No. 104 Renmin South Road, Qingjiangpu District, Huai’an 223002, Jiangsu Province, China. aa14756893@163.com
Received: August 15, 2023 Peer-review started: August 15, 2023 First decision: August 31, 2023 Revised: September 11, 2023 Accepted: September 18, 2023 Article in press: September 18, 2023 Published online: October 26, 2023 Processing time: 70 Days and 22.5 Hours
ARTICLE HIGHLIGHTS
Research background
Breast infiltrating ductal carcinoma (BIDC) represents the largest heterotypic tumor group, and this study analyzed the clinical significance of forkhead box M1 (FOXM1), cyclooxygenase-2 (COX-2), and glucose-regulated protein 78 (GRP78) in BIDC, which could provide a reliable foundation for subsequent studies.
Research motivation
FOXM1, COX-2, and GRP78 are closely related to breast cancer development and progression, but their roles in BIDC remain unclear. They may play equally important roles and hold promise for future diagnosis and treatment of BIDC.
Research objectives
To analyze the clinical significance of FOXM1, COX-2, and GRP78 in BIDC, and to provide references and new research directions for future diagnosis and treatment of BIDC.
Research methods
In this study, we analyzed the clinical significance of FOXM1, COX-2, and GRP78 in BIDC by detecting the expression levels of FOXM1, COX-2, and GRP78 in the peripheral blood of patients with BIDC and healthy people.
Research results
FOXM1, COX-2, and GRP78 were elevated in BIDC and demonstrated excellent diagnostic and prognostic assessment of BIDC.
Research conclusions
FOXM1, COX-2, and GRP78 exhibit abnormally high expression in BIDC, promoting malignant tumor development and closely correlating with prognosis.
Research perspectives
This study demonstrated the clinical significance of FOXM1, COX-2, and GRP78 in BIDC, and in the future, they can be used in the clinic as reference indexes for the diagnosis, disease evaluation, and prognosis assessment of BIDC. In addition, they can also be used as targets to study new targeted therapeutic options for BIDC in the future.
